Skip to Content
Explore our new website! Designed to better serve patients, partners and the Crinetics community in the next generation of endocrinology care.

News & Events

Show:

Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences

Crinetics management will participate in fireside chats at the 6th Annual Evercore ISI HealthCONx Conference on November 28 and the...

READ MORE

6th Annual Evercore ISI HealthCONx Conference

Event Date: November 28, 2023

READ MORE

Crinetics Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics granted non-qualified stock option awards to purchase an aggregate of 83,600 shares of its common stock to four new...

READ MORE

Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Crinetics Pharmaceuticals reported financial results and provided an update on third quarter 2023 progress

READ MORE

Crinetics Announces October 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics granted non-qualified stock option awards to purchase an aggregate of 619,100 shares of its common stock to eleven new...

READ MORE

Cantor Global Healthcare Conference 2023

Event Date: September 26, 2023

READ MORE

Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023

Crinetics management will participate in a fireside chat and conduct investor meetings at the Cantor Global Healthcare Conference on September...

READ MORE

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Crinetics intends to use the net proceeds from the offering to fund the development of paltusotine, CRN04894 and its other...

READ MORE

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

Crinetics announced today that it intends to offer and sell, subject to market and other conditions, $250.0 million of shares...

READ MORE